Martin A. Lehr - Oct 22, 2021 Form 4/A - Amendment Insider Report for Context Therapeutics Inc. (CNTX)

Role
Chief Executive Officer, Director
Signature
/s/ Alex Levit, Attorney-in-Fact
Stock symbol
CNTX
Transactions as of
Oct 22, 2021
Transactions value $
$426,135
Form type
4/A - Amendment
Date filed
12/17/2021, 03:18 PM
Date Of Original Report
Oct 22, 2021
Previous filing
Oct 19, 2021
Next filing
Dec 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTX Common Stock Exercise of out-of-the-money derivative security $376K +52.7K $7.14* 0 Oct 22, 2021 Martin Lehr 2000 Trust
transaction CNTX Common Stock Conversion of derivative security +211K 211K Oct 22, 2021 Martin Lehr 2000 Trust F1
transaction CNTX Common Stock Conversion of derivative security +586K +278.33% 797K Oct 22, 2021 Martin Lehr 2000 Trust F2
transaction CNTX Common Stock Purchase $50K +10K +1.25% $5.00 807K Oct 22, 2021 Martin Lehr 2000 Trust
holding CNTX Common Stock 89.6K Oct 22, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTX Warrant (right to buy) Exercise of out-of-the-money derivative security $0 +52.7K $0.00* 0 Oct 22, 2021 Common Stock 52.7K $7.14 Martin Lehr 2000 Trust
transaction CNTX Series A Preferred Stock Conversion of derivative security -211K -100% 7 Oct 22, 2021 Common Stock 211K Martin Lehr 2000 Trust F1, F3
transaction CNTX Series Seed Preferred Stock Conversion of derivative security -586K -100% 1 Oct 22, 2021 Common Stock 586K Martin Lehr 2000 Trust F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
F2 Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
F3 Fully vested.

Remarks:

The attached amends and restates the Form 4 filed on October 25, 2021 in its entirety